HUE027440T2 - C-19 szteroidok specifikus gyógyászati alkalmazásokra - Google Patents
C-19 szteroidok specifikus gyógyászati alkalmazásokra Download PDFInfo
- Publication number
- HUE027440T2 HUE027440T2 HUE12171940A HUE12171940A HUE027440T2 HU E027440 T2 HUE027440 T2 HU E027440T2 HU E12171940 A HUE12171940 A HU E12171940A HU E12171940 A HUE12171940 A HU E12171940A HU E027440 T2 HUE027440 T2 HU E027440T2
- Authority
- HU
- Hungary
- Prior art keywords
- compound
- use according
- collagen
- hydrogen
- effects
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pregnancy & Childbirth (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
- ΛΪ r * S.>WS5· 713878/ZSÖ EP2500082 C-18 szteroidok specifikus gyógyászati alkalmazásokra Szabadalmi igénypontok 1 képleti vágyóiét, ahola, b síiéivé c egymástól függetlenül kémiai kötés vagy keítöskötés; Rí hidrogénatom vagy 1-8 szénatomos alksicsoport; Re ΟΒδ csoport, ahol Rs hidrogénatom vagy 1*6 szénatomos egyenes láncú vagy elágazó láncú aikilesopod:; R& ha e jelenese kémiai kötés, hidrogénatom vagy 1-6 szénatomos alksicsoport, vagy ha c jelentése kettőskötés, CHR5 csoport, ahol R5 a fentiekben megadott; R« hidrogénatom, 1-8 szénatomos aíkíicsoport, szubszfituálatfan vagy 1-6 szénatomos aikilcsoporttal szubszituálí fenlícsoport, 00¾ adlcsoport (ahol R§ hidrogénatom; 1-6 szénatomos egyenes iánoú vagy elágazó láncú aíkíicsoport; szubsztituálatian vagy 1-8 szénatomos aikicsoporttal szubsztituáit ienll vagy benzoitesoport), és sói; az alábbi megelőzésben és/vagy kezelésben történő alkalmazásra: bőr terápiás kezelése, ahol a kollagén erősítése, stabilizálása és/vagy növelése a cél. cefiyiíttői eltérő célokra; ahol ezek a rendellenességek a bőrnek nap áltat történő kollagén szintézist stimuláló terápiás kezelés, anaholikus hatáson keresztül, ínszalagoknál, inaknál, porcoknál, csontoknál, dsnfnoél és artériáknál, vénáknál vagy húgyvezetékeknél történő alkalmazáskor; szívizom- és agyi infarktus; érelmeszesedés; vizeleti inkcntineneía; csontritkulás; és roastaigia; és hormon helyettesítési terápiában részesülő nőkön történő alkalmazásra.
- 2. Vegyület az í. igénypont szerinti alkalmazásra, ahol a és a kémiai kötés, b kettős kötés, és R2 jelentése ORs csoport,: ahol Of% jelentése az 1. Igénypontban megadott.
- 3. Vegyület az 1. vagy 2. igénypont szerinti alkaimazásra, ahol a vogyütetet hefyileg alkalmazzuk,
- 4. Vegyüíet az előző igénypontok bármelyike szerinti alkaimazásra, ahol a megelőző és/vagy lerágás hatást alkaímazást olyan körülmények között hozzuk létre, ahol fokozott anaboíikus aktivitás jön létra, miközben az androgén hatás eltűnik.
- 5. Vegyület a 4. Igénypont szerinti alkalmazásra, ahol a fokozott anaboíikus létrejötte aktivitás kollagén stabiiizási, növekedési és erősödés! hatás bármelyikével jár együtt.
- 6. Vegyület a 4. vagy 5. igénypont szerinti alkalmazásra, ahol a fokozott anaboíikus aktivitás létrejöttét a kollagén termelés fokozódása határozza meg. ?, Vegyület az előző igénypontok bármelyike szerinti alkalmazásra, ahol a megelőző és/vagy terápiás hatást olyan körülmények között hozzuk létre, ahol a természetes androgén kötődése ellen az AR»re mutatott gátló hatás jön létre.
- 8. Vegyület az előző igénypontok bármelyike szerinti alkalmazásra, ahol a megelőző és/vagy terápiás hatást olyan körülmények között hozzuk tétre, ahol a következő hatások, külön vagy kombinációban, jönnek létre: * a vegyület nem aromaflzálódik arematázzai; * a vegyület nem redukálédik őo-reduktázzal; * a vegyület gátolja az So-reduktázt; «C-17 oxidált metabolitja alakjában, a vegyület fokozott aromatáz gátlást mutat.
- 9, Vegyület az előző igénypontok bármelyike szerinti alkalmazásra:, ahol a vegyület 4-hidroxitesztoszteron vagy sója vagy a 4~hidroxitesztoszteron egy észtere, melyben a 4» hídroxitesztoszteron az 1. igénypont szerinti R,i csoport £Öf% aciicsoportnak megfelelően észferezett.
- 10, Vegyüíet az előző Igénypontok bármelyike szerinti alkalmazásra, meiy az 1. igénypőet szerinti vegyűiettőí eltérő 5a*redukiáz inhibitorok és antíandrogének közűi választott vegyüíetteí kombinált.
- 11, Vegyüíet az előző igénypontok bármelyike szerinti alkalmazásra, ahol a vegyöletet gyógyászati készítmény formájában alkalmazzuk, mely továbbá dimetiblzoszorhiciof is tartalmaz.
- 12, Vegyüíet a 11. igénypont szerinti alkalmazásra, ahol a gyógyászati készítmény toplkáiís formává alakított. 13,képioiü vegyüíet, ahol a, b illetve c egymástól függetlenül kémiai kötés vagy kettőskötés; R-, hícirogénaíöm vagy 1-6 szénatomos aikílcsopört; R2 OR& csoport, ahol Rs hidrogénatom vagy 1*6 szénatomos egyenes láncú vagy elágazó láncú aikílcsoport; %, ba c Jelentése kémiai kötés, hidrogénatom vagy 1-6 szénatomos aikílcsoport, vagy ha c Jelentése ketfőskötés, €t#l§ csoport, ahol R5 a fentiekben megadott; H4 hidrogénatom, 1-6 szénatomos aikílcsoport, szubsztituáíaíian vagy 1-6 szénatomos afkiíosoporttaí szubsztituált fénitcsopört, €0RS acílcsopirt (ahol Rs hidrogénatom; 1*6 szénatomos egyenes láncú vagy elágazó láncú aikílcsoport; szubsztituálatlan vagy 1*6 szénatomos álkicsoporttai szubsztituált fenii vagy benzoilcsoport), és sói; szívizom és agyi infarktus, érelmeszesedés; vizelet! Inkonfinencia; és a bőrnek nap által történő behatásából adódó rendellenességek, ahol a kollagén erősítése, stabilizálása és/vagy növelése a cél; csontritkulás; mastalgia megelőzésében és/vagy kezelésében történő alkalmazásra,; és hormon helyettesítési terápiában részesülő nőkön történő alkalmazásra, ahol a megelőzésben és kezelésben történő alkalmazás anabolikus hatással függ össze.
- 14. Vegyület a 13. Igénypont szerinti alkalmazásra, ahol a fokozott anabolikus létrejötte aktivitás kollagén stabilitási,, növekedési és erősödés; hatás bármelyikével jár együtt.
- 15. Vegyület a 13. vagy 14. igénypont szerinti alkalmazásra, ahol a fokozott anabolikus aktivitás létrejöttét a kollagén termetes fokozódása határozza meg.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07022016.5A EP2060300B1 (en) | 2007-11-13 | 2007-11-13 | C-19 steroids for therapeutic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE027440T2 true HUE027440T2 (hu) | 2016-10-28 |
Family
ID=39183133
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12171940A HUE027440T2 (hu) | 2007-11-13 | 2007-11-13 | C-19 szteroidok specifikus gyógyászati alkalmazásokra |
HUE12194964A HUE025577T2 (hu) | 2007-11-13 | 2008-11-12 | C-19 szteroidok gyógyászati alkalmazásokra |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE12194964A HUE025577T2 (hu) | 2007-11-13 | 2008-11-12 | C-19 szteroidok gyógyászati alkalmazásokra |
Country Status (17)
Country | Link |
---|---|
US (1) | US10265328B2 (hu) |
EP (5) | EP2060300B1 (hu) |
JP (1) | JP6025301B2 (hu) |
KR (2) | KR20160036100A (hu) |
CN (1) | CN101854979B (hu) |
AU (1) | AU2008323199B2 (hu) |
CA (1) | CA2705533C (hu) |
CY (1) | CY1116496T1 (hu) |
DK (4) | DK2060300T3 (hu) |
ES (4) | ES2628507T3 (hu) |
HK (1) | HK1148704A1 (hu) |
HR (1) | HRP20150715T1 (hu) |
HU (2) | HUE027440T2 (hu) |
PL (4) | PL2500062T3 (hu) |
PT (3) | PT2060300E (hu) |
SI (1) | SI2564900T1 (hu) |
WO (1) | WO2009062683A1 (hu) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2964323B1 (fr) * | 2010-09-08 | 2012-11-09 | Jean Pierre Raynaud | Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate |
KR20140033408A (ko) * | 2011-05-15 | 2014-03-18 | 트리멜 바이오파마 에스알엘 | 비내용 테스토스테론 겔의 조절된 방출, 경비성 투여를 위한 방법 및 미리-충전된 다회 용량 도포기 시스템 |
AU2014252652A1 (en) * | 2013-04-10 | 2015-11-26 | Glycobiosciences, Inc. | Topical nutraceutical composition |
SI3040075T1 (en) * | 2014-12-30 | 2018-04-30 | Curadis Gmbh | C-19 STEROIDS FOR INHIBITION OF NEVASCULARIZATION |
EP3632445A1 (en) * | 2018-10-04 | 2020-04-08 | Curadis GmbH | Combinations with a c-19 steroid for treating cancers |
CN112972465B (zh) * | 2021-02-22 | 2022-09-13 | 复旦大学附属中山医院 | 一种雄激素受体拮抗剂在制备治疗心血管疾病药物中的应用 |
KR102554865B1 (ko) | 2021-10-05 | 2023-07-12 | 경상북도(농업기술원) | 친환경 덩굴 절단 파쇄장치 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2762818A (en) | 1955-05-26 | 1956-09-11 | Searle & Co | 4-hydroxytestosterone and esters thereof |
DE3121152A1 (de) * | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie" |
DE3121153A1 (de) * | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie" |
JPS62132810A (ja) | 1985-12-05 | 1987-06-16 | Shiseido Co Ltd | 化粧料 |
GB8721384D0 (en) | 1987-09-11 | 1987-10-21 | Erba Farmitalia | 17-substituted andro-sta-1 4-dien-3-one derivatives |
US4895715A (en) * | 1988-04-14 | 1990-01-23 | Schering Corporation | Method of treating gynecomastia |
GB9021546D0 (en) | 1990-10-04 | 1990-11-21 | Beecham Group Plc | Novel composition |
JPH06502161A (ja) | 1990-10-31 | 1994-03-10 | ビーチャム・グループ・パブリック・リミテッド・カンパニー | レチノイド浸透作用エンハンサーを含む局所用組成物 |
DE4405898A1 (de) | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
US5824326A (en) | 1997-06-27 | 1998-10-20 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Activity enhancement of ferulic acid with dimethyl isosorbride in cosmetic compositions |
EP2322182A1 (en) * | 1999-09-30 | 2011-05-18 | Harbor BioSciences, Inc. | Androstenol derivatives as androgen receptor modulator |
GB9930839D0 (en) | 1999-12-30 | 2000-02-16 | Pharmacia & Upjohn Spa | Process for treating gynecomastia |
GB0012293D0 (en) | 2000-05-23 | 2000-07-12 | Astrazeneca Ab | Pharmaceutical combination |
US6242436B1 (en) * | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
US7253210B2 (en) * | 2002-10-15 | 2007-08-07 | University Of Tennessee Research Foundation | Methylene-bridged selective androgen receptor modulators and methods of use thereof |
JP2005507886A (ja) * | 2001-09-21 | 2005-03-24 | メルク エンド カムパニー インコーポレーテッド | アンドロゲン受容体調節剤としてのアンドロスタン類 |
US6586417B1 (en) * | 2002-04-22 | 2003-07-01 | Nutrisport Pharmacal, Inc. | Ester and ether derivatives of 4-hydroxy 4-androstene-3,17-dione and a method for the regulation of athletic function in humans |
US20030199487A1 (en) | 2002-04-22 | 2003-10-23 | Mr. Vince Paternoster | Ester and ether derivatives of 4-hydroxytestosterone and a method for the regulation of athletic function in humans |
US20030229063A1 (en) | 2002-06-05 | 2003-12-11 | Llewellyn William Charles | Use of 4-hydroxytestosterone to lower estrogen levels in humans |
US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
US20080207545A1 (en) | 2003-10-21 | 2008-08-28 | Hoke Glenn D | Methods and Compositions for Treating 5Alpha-Reductase Type 1 and Type 2 Dependent Conditions |
CA2549518A1 (en) | 2003-12-12 | 2005-07-14 | University Of Rochester | Non-androgen dependent roles for androgen receptor and non-androgen related inhibitors of androgen receptor |
JP2008007404A (ja) * | 2004-10-08 | 2008-01-17 | Nippon Kayaku Co Ltd | 新規ピリジン誘導体 |
US20090062258A1 (en) * | 2005-02-03 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
WO2006084312A1 (en) | 2005-02-09 | 2006-08-17 | Acrux Dds Pty Ltd | Method of promoting hair growth |
JP4755845B2 (ja) | 2005-04-28 | 2011-08-24 | 共栄化学工業株式会社 | テストステロン−5α−リダクターゼ阻害剤及びテストステロン−5α−リダクターゼ阻害剤を含有する化粧料。 |
EP1854465A1 (en) * | 2006-05-12 | 2007-11-14 | Alexander Tobias Teichmann | Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers |
ES2574933T3 (es) * | 2007-11-13 | 2016-06-23 | Athenion Ag | Esteroides de C-19 para usos cosméticos |
-
2007
- 2007-11-13 PL PL12171940T patent/PL2500062T3/pl unknown
- 2007-11-13 DK DK07022016.5T patent/DK2060300T3/da active
- 2007-11-13 PT PT70220165T patent/PT2060300E/pt unknown
- 2007-11-13 EP EP07022016.5A patent/EP2060300B1/en active Active
- 2007-11-13 HU HUE12171940A patent/HUE027440T2/hu unknown
- 2007-11-13 EP EP12171940.5A patent/EP2500062B1/en active Active
- 2007-11-13 DK DK12171940.5T patent/DK2500062T3/en active
- 2007-11-13 ES ES15172134.7T patent/ES2628507T3/es active Active
- 2007-11-13 ES ES12171940.5T patent/ES2547339T3/es active Active
- 2007-11-13 PT PT121719405T patent/PT2500062E/pt unknown
- 2007-11-13 PL PL15172134T patent/PL2949361T3/pl unknown
- 2007-11-13 EP EP15172134.7A patent/EP2949361B1/en not_active Not-in-force
- 2007-11-13 PL PL07022016T patent/PL2060300T3/pl unknown
- 2007-11-13 DK DK15172134.7T patent/DK2949361T3/en active
- 2007-11-13 ES ES07022016.5T patent/ES2539800T3/es active Active
-
2008
- 2008-11-12 WO PCT/EP2008/009541 patent/WO2009062683A1/en active Application Filing
- 2008-11-12 AU AU2008323199A patent/AU2008323199B2/en not_active Ceased
- 2008-11-12 PT PT121949648T patent/PT2564900E/pt unknown
- 2008-11-12 EP EP10165423A patent/EP2260903A1/en not_active Ceased
- 2008-11-12 JP JP2010533487A patent/JP6025301B2/ja not_active Expired - Fee Related
- 2008-11-12 ES ES12194964.8T patent/ES2543047T3/es active Active
- 2008-11-12 HU HUE12194964A patent/HUE025577T2/hu unknown
- 2008-11-12 PL PL12194964T patent/PL2564900T3/pl unknown
- 2008-11-12 KR KR1020167007505A patent/KR20160036100A/ko active Search and Examination
- 2008-11-12 CN CN200880115837.3A patent/CN101854979B/zh not_active Expired - Fee Related
- 2008-11-12 CA CA2705533A patent/CA2705533C/en not_active Expired - Fee Related
- 2008-11-12 EP EP20120194964 patent/EP2564900B1/en active Active
- 2008-11-12 SI SI200831456T patent/SI2564900T1/sl unknown
- 2008-11-12 KR KR1020107010503A patent/KR20100094975A/ko active Search and Examination
- 2008-11-12 DK DK12194964.8T patent/DK2564900T3/en active
- 2008-11-12 US US12/734,616 patent/US10265328B2/en not_active Expired - Fee Related
-
2011
- 2011-03-18 HK HK11102722.8A patent/HK1148704A1/zh not_active IP Right Cessation
-
2015
- 2015-07-01 HR HRP20150715TT patent/HRP20150715T1/hr unknown
- 2015-07-16 CY CY20151100620T patent/CY1116496T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2500062T3 (en) | C-19 steroids to specific therapeutic applications, | |
US8258123B2 (en) | C-19 steroids for cosmetic and further uses | |
SK286051B6 (sk) | Použitie prekurzora pohlavného steroidu na prípravu liečiva na prevenciu alebo liečenie znížených alebo nevyrovnaných koncentrácií pohlavných steroidov | |
Rasmusson et al. | Therapeutic control of androgen action | |
EP3860611A1 (en) | Medication against estrogen-receptor ss (erss) positive breast tumor | |
Watson et al. | Testosterone hormone replacement and its alternatives |